F98 -质粒载体-ATCC-DSM-CCUG-泰斯拓生物

你好，请登录   免费注册    |    收藏本站
联系电话: 0574-87917803
你好,请登录   免费注册 | 收藏
联系电话: 0574-87917803
热门搜索: 金黄色葡萄球菌 铜绿假单胞菌 红菇 香菇
F98
F98
规格:
货期:
编号:TS161872
品牌:Testobio
产品名称： F98 EGFR
商品货号： TS161872
Organism： Rattus norvegicus, rat
Tissue： brain
Product Format： frozen
Morphology： glial
Culture Properties： adherent
Biosafety Level： 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease： undifferentiated malignant glioma
Age： fetus, 20 days gestation
Applications：

This cell line has been used for in vivo studies of molecular targeting of EGFR in synegeneic Fischer Rats using either the ligand EGF RefBarth RF, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 62(11): 3159-3166, 2002. PubMed: 12036929 or monoclonal antibodies directed against it. RefWu G, et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 13(4): 1260-1268, 2007. PubMed: 17317838
Storage Conditions： liquid nitrogen vapor phase
Images：
Derivation：
The F98EGFR was produced by transfecting parental F98 rat glioma cells (ATCC CRL-2397) with an expression vector containing human, wildtype EGFR cDNA.
Receptor Expression：
Epidermal Growth Factor Receptor (EGFR), expressed (verified at ATCC)
Tumorigenic： YES
Effects：
tumorigenic in syngeneic Fischer rats
Comments：

F98EGFRxa0cells express approximately 5 x 105 non-functional EGFR sites per cell compared with an undetectable number of EGFR sites on F98 parental cells.
Complete Growth Medium： The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium:
  • 0.2 mg/ml G -418
  • fetal bovine serum to a final concentration of 10%
    • Subculturing：
    Volumes used in this protocol are for 75 cm2 flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
    1. Remove and discard culture medium.
    2. Briefly rinse the cell layer with Ca++/Mg++ free Dulbeccos phosphate-buffered saline (D-PBS) or 0.05% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
    3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
      Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
    4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
    5. Add appropriate aliquots of the cell suspension to new culture vessels.


    Note: If cells are cultured continuously, add 0.6 mg/mL G-418 to the complete growth medium for a passage about once a month.

    Subcultivation ratio: A subcultivation ratio of 1:6 to 1:10 is recommended.

    Medium renewal: Every 2 to 3 days.
    Cryopreservation：
    Freeze medium: complete growth medium, 95%; DMSO, 5%
    liquid nitrogen vapor phase
    Culture Conditions：
    Temperature: 37°C
    Atmosphere: air, 95%; carbon dioxide (CO2), 5%
    Name of Depositor： RF Barth
    Year of Origin： May 1999
    References：

    Yang W, et al. Convection enhanced delivery of boronated epidermal growth factor for molecular targeting of EGFR positive gliomas. Cancer Res. 62: 6552-6558, 2002. PubMed: 12438250

    Barth RF, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 62(11): 3159-3166, 2002. PubMed: 12036929

    Wu G, et al. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. 5(1): 52-59, 2006. PubMed: 16432162.

    Wu G, et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 13(4): 1260-1268, 2007. PubMed: 17317838

    Yang W, et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res. 14(3): 883-891, 2008. PubMed: 18245552

    首页 > 产品中心 > 微生物培养 > 菌株 > null > F98

    产品中心 Product Center

    联系我们CONTACT US

    • 0574-87917803
      24小时服务热线
    • testobio@163.com
      销售邮箱
    • 浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
      地址

    联系方式

    • 章丽敏
      17757489010
    • 朱静
      18067106081
    • 李晴
      18067408036
    • 李晶晶
      13375187189
    • 周雪
      13372109301

    F98

    • 货号: TS161872
    • 好评
    有货
    • 品牌 : TESTOBIO
    产品名称： F98 EGFR
    商品货号： TS161872
    Organism： Rattus norvegicus, rat
    Tissue： brain
    Product Format： frozen
    Morphology： glial
    Culture Properties： adherent
    Biosafety Level： 2

    Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
    Disease： undifferentiated malignant glioma
    Age： fetus, 20 days gestation
    Applications：

    This cell line has been used for in vivo studies of molecular targeting of EGFR in synegeneic Fischer Rats using either the ligand EGF RefBarth RF, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 62(11): 3159-3166, 2002. PubMed: 12036929 or monoclonal antibodies directed against it. RefWu G, et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 13(4): 1260-1268, 2007. PubMed: 17317838
    Storage Conditions： liquid nitrogen vapor phase
    Images：
    Derivation：
    The F98EGFR was produced by transfecting parental F98 rat glioma cells (ATCC CRL-2397) with an expression vector containing human, wildtype EGFR cDNA.
    Receptor Expression：
    Epidermal Growth Factor Receptor (EGFR), expressed (verified at ATCC)
    Tumorigenic： YES
    Effects：
    tumorigenic in syngeneic Fischer rats
    Comments：

    F98EGFRxa0cells express approximately 5 x 105 non-functional EGFR sites per cell compared with an undetectable number of EGFR sites on F98 parental cells.
    Complete Growth Medium： The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium:
  • 0.2 mg/ml G -418
  • fetal bovine serum to a final concentration of 10%
    • Subculturing：
    Volumes used in this protocol are for 75 cm2 flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
    1. Remove and discard culture medium.
    2. Briefly rinse the cell layer with Ca++/Mg++ free Dulbeccos phosphate-buffered saline (D-PBS) or 0.05% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
    3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
      Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
    4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
    5. Add appropriate aliquots of the cell suspension to new culture vessels.


    Note: If cells are cultured continuously, add 0.6 mg/mL G-418 to the complete growth medium for a passage about once a month.

    Subcultivation ratio: A subcultivation ratio of 1:6 to 1:10 is recommended.

    Medium renewal: Every 2 to 3 days.
    Cryopreservation：
    Freeze medium: complete growth medium, 95%; DMSO, 5%
    liquid nitrogen vapor phase
    Culture Conditions：
    Temperature: 37°C
    Atmosphere: air, 95%; carbon dioxide (CO2), 5%
    Name of Depositor： RF Barth
    Year of Origin： May 1999
    References：

    Yang W, et al. Convection enhanced delivery of boronated epidermal growth factor for molecular targeting of EGFR positive gliomas. Cancer Res. 62: 6552-6558, 2002. PubMed: 12438250

    Barth RF, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 62(11): 3159-3166, 2002. PubMed: 12036929

    Wu G, et al. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. 5(1): 52-59, 2006. PubMed: 16432162.

    Wu G, et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 13(4): 1260-1268, 2007. PubMed: 17317838

    Yang W, et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res. 14(3): 883-891, 2008. PubMed: 18245552

    扫码关注小红书账号
    关注我们
    联系电话：0574-87917803
    章丽敏：17757489010
    朱静：18067106081
    李晴：18067408036
    李晶晶：13375187189
    周雪：13372109301
    邮箱：testobio@163.com
    地址：浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
    在线留言
    合作单位: